Amgen
The Lead
Astellas, Amgen to Form Joint Venture in Japan
May 29, 2013 7:56 am | News | Comments
Tokyo-based Astellas Pharma Inc. said today it will form a joint venture with major U.S. biotechnology company Amgen Inc. to develop and market drugs in Japan. The new company will start business operations in October to develop five drugs, including for gastric cancer and osteoporosis, under a plan to launch drug sales in 2016.
Astellas, Amgen to Form Joint Venture in Japan
May 29, 2013 7:56 am | News | Comments
Tokyo-based Astellas Pharma Inc. said today it will form a joint venture with...
Astellas, Amgen to Form Joint Venture in Japan
May 29, 2013 7:56 am | News | Comments
Tokyo-based Astellas Pharma Inc. said today it will form a joint venture with...
FREE Daily Email Newsletter
FDA Backs New for Amgen Drug for Rare Bone Tumors
June 14, 2013 8:29 am | by The Associated Press | News | CommentsAmgen Inc. said yesterday that the Food and Drug Administration has approved a new use for its bone drug Xgeva. The company, based in Thousand Oaks, Calif., said it now can market Xgeva for treating a rare condition, giant cell tumor of bone, when surgery isn't practical.
Amgen and Novartis Join Atlas Venture Fund IX As Corporate Strategic Partners
May 17, 2013 8:16 am | News | CommentsAtlas Venture has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners.
Earnings Preview: Amgen Reports 1Q results Tuesday
April 19, 2013 8:01 am | by LINDA A. JOHNSON,AP Business Writer | News | CommentsBiotech drugmaker Amgen Inc. will focus on recent results on a key experimental melanoma drug, testing of other drugs and revenue from its top-selling drugs when it reports first-quarter results after the stock market closes Tuesday. The world's biggest biotech company will discuss promising preliminary results in a late-stage study of its experimental drug for the deadly skin cancer melanoma
Amgen to Pay $25M to Resolve Kickback Case
April 16, 2013 6:37 pm | by The Associated Press | News | CommentsThe U.S. Department of Justice said Tuesday that biotech drugmaker Amgen Inc. will pay $24.9 million to resolve claims it paid kickbacks to increase sales of its anemia drug Aranesp. The Justice Department said Amgen paid kickbacks to Omnicare Inc. and PharMerica Corp., which sell drugs to...
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
March 20, 2013 7:52 am | News | CommentsAmgen today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).
Drugmakers, Interpol Ramp Up Fight Against Fakes
March 12, 2013 1:01 am | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | CommentsMore than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
FDA Halts Amgen Study After Teen Patient Death
February 27, 2013 7:55 am | News | CommentsFederal health regulators have halted Amgen's studies of its drug Sensipar after the death of a 14-year-old patient in a company trial. The Food and Drug Administration said Tuesday it is still gathering information about the death, but has shut down all studies of the drug in children.
Amgen Rises on Recall of Affymax Anemia Drug
February 26, 2013 8:07 am | News | CommentsShares of Amgen Inc. rose Monday after a drug that competes with Amgen's anemia treatment Aranesp and Epogen was taken off the market because of severe allergic reactions and deaths in some patients. Affymax Inc. and Takeda Pharmaceutical Co. issued a recall of their anemia drug Omontys on Saturday, saying dialysis centers should stop using it.
Selexis Announces Expansion of R&D License Agreement with Amgen
February 20, 2013 7:56 am | News | CommentsSelexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line for research and development.
Amgen, UCB Halt Testing of Fracture-Healing Drug
February 11, 2013 4:34 pm | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | CommentsBiotech giant Amgen Inc. and Belgian drugmaker UCB SA have scrapped plans for late-stage testing of an experimental treatment for accelerated healing of fractures, but will continue testing their drug for a much bigger and potentially lucrative market, treating osteoporosis in postmenopausal...
Amgen Outlines Long-Term Strategy
February 7, 2013 7:57 am | News | CommentsAmgen today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming the company's core strategy will continue to focus on innovation, discovery and development of breakthrough molecules.
Bind and Amgen in $180M Cancer Drug Research Deal
January 9, 2013 3:12 am | News | CommentsNEW YORK (AP) — Drug developer Bind Biosciences said Tuesday that it will study potential cancer treatments with biotechnology company Amgen Inc. as part of a deal that could be worth more than $180 million.
Amgen Takes Third License for Rights to Use ImmunoGen’s TAP Technology
December 19, 2012 3:25 am | News | CommentsImmunoGen, Inc, a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Amgen has licensed the exclusive right to use the Company’s maytansinoid TAP technology to develop anticancer therapeutics to a third target, which is undisclosed.
Amgen to Acquire deCODE Genetics
December 10, 2012 3:24 am | News | CommentsAmgen will acquire deCODE Genetics in a deal valued at $415M ...
FDA Approves New Indication For Prolia
September 21, 2012 3:53 am | News | CommentsAmgen today announced the FDA approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
Amgen Ends Phase 3 Pancreatic Cancer Drug Study
August 9, 2012 4:14 am | News | CommentsAmgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.
Amgen Second Quarter Report to Focus on New Drugs, Recent Deals
July 25, 2012 4:35 am | by LINDA A. JOHNSON,AP Business Writer | News | CommentsTRENTON, N.J. (AP) — Amgen Inc., the world's biggest biotech company, will focus on early sales of some promising new drugs, progress in its experimental pipeline of new drugs and three recent deals when it reports its second-quarter results after the stock market closes Thursday.
Amgen Closes $315M Buyout of KAI Pharmaceuticals
July 6, 2012 5:33 am | by the Associated Press | News | CommentsAmgen Inc. said Thursday it completed its acquisition of KAI Pharmaceuticals for $315 million.
West Announces Technology Agreement with Amgen
June 21, 2012 4:23 am | News | CommentsWest Pharmaceutical Services, Inc., a global manufacturer of components and systems for injectable drug delivery, today announced an agreement with Amgen Inc., a biotechnology pioneer and one of the world's leading independent biotechnology companies, to evaluate Daikyo Crystal Zenith technologies for drug containment.
Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
June 13, 2012 4:02 am | News | CommentsAmgen has announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals, a privately held Turkish company.
M & A Activity Heats Up In April
May 1, 2012 5:35 am | News | CommentsApril proved to be a big month for M&A activity as companies announced more than $29 billion in agreed upon transactions during the month, the bulk of which occurred during the final week.
Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
April 25, 2012 9:21 am | by Amgen | News | CommentsAcquisition Will Build on Amgen’s Existing Business and Provide a Platform for Growth in Turkey and This Strategically Important Region THOUSAND OAKS, Calif. and ISTANBUL, April 25, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN), the world’s largest biotechnology company, and...
Amgen First Quarter Profit up 5%, Beats Wall Street Views
April 25, 2012 4:08 am | by LINDA A. JOHNSON,AP Business Writer | News | CommentsTRENTON, N.J. (AP) — Biotech giant Amgen Inc. said Tuesday that its first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street forecasts.
Amgen Buying Turkey's Mustafa Nevzat for $700M
April 25, 2012 4:01 am | News | CommentsAmgen is buying Turkish pharmaceutical company Mustafa Nevzat Pharmaceuticals for $700 million as part of its international expansion plans.
A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)
April 24, 2012 9:21 am | by Amgen | News | CommentsTHOUSAND OAKS, Calif., April 23, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away.
